Get informed when a big investor buys or sells
+ FollowOvervalued by 68.7% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $10.02 Million |
|---|---|
| Enterprise Value | $40.18 Million |
| Earnings per Share | $-67.5 |
| Beta | 3.98 |
| Outstanding Shares | 1,584,633 |
| P/E Ratio | -0.08 |
|---|---|
| PEG | -0.05 |
| Price to Sales | 0.01 |
| Price to Book Ratio | -0.25 |
| Enterprise Value to Revenue | 0.08 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.81 |
| Debt to Equity | -1.67 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 5.11%▲ 1.53% |
|---|---|
| Total Invested | $709,081▲ 75.03% |
| Investors Holding | 16▲ 2.00% |
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops ...